The AGGF1 Knockout MCF-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the MCF-7 human breast epithelial cell line. This polyclonal pool comprises a heterogeneous mix of AGGF1-disrupted alleles, establishing a loss-of-function model suitable for investigating AGGF1-dependent processes without the artifacts of single-cell cloning. The polyclonal format provides a robust system for functional studies where population-level effects are desired.
The MCF-7 host line is an ER-positive, PR-positive, wild-type p53 human breast adenocarcinoma cell line originally derived from the pleural effusion of a patient with metastatic mammary carcinoma. It serves as a widely adopted model for hormone-responsive breast cancer research, offering well-defined signaling networks that facilitate the dissection of crosstalk between endocrine pathways and oncogenic mechanisms.
AGGF1 encodes a secreted angiogenic factor that is transcriptionally regulated by hypoxia through HIF1A. Following secretion, AGGF1 binds to endothelial cells and activates both the PI3K-Akt and MAPK/ERK signaling cascades, resulting in phosphorylation of AKT1 and ERK and consequent promotion of endothelial cell proliferation and migration. AGGF1 directly interacts with KRIT1, a protein critical for endothelial junction stability; disruption of this complex is linked to vascular malformations such as Klippel-Trenaunay syndrome. Thus, AGGF1 functions as a hypoxia-responsive mediator that couples HIF1A signaling to VEGF-dependent angiogenesis, with AKT1 and ERK serving as key downstream effectors.
In the context of MCF-7 breast cancer cells, knockout of AGGF1 enables precise interrogation of its role in paracrine angiogenic signaling. Researchers can determine whether ER-positive tumor cells require AGGF1 to stimulate endothelial cell responses and assess the dependency of AKT and ERK activation on AGGF1 in a hormone-sensitive background. This model also supports investigation of AGGF1-related vascular anomaly pathways and evaluation of anti-angiogenic therapeutic strategies.
Typical applications include western blotting and RT-qPCR for verifying AGGF1 ablation, phospho-specific analysis of AKT and ERK, co-culture endothelial tube formation assays, wound healing, Transwell invasion, and in vivo xenograft tumor studies. These polyclonal knockout cells therefore serve as a versatile tool for target validation, pathway dissection, and drug screening in breast cancer angiogenesis research. For further technical information or ordering, please contact Ascent Research.
